Cammaro has secured a funding facility and stabilisation loan from Paragon Bank’s Development Finance division for a new £32m, 138-unit purpose-built student accommodation ...

The scheme is located in the popular Orchard Park area, just outside Cambridge city centre and close to nearby universities, including the University of Cambridge and Anglia Ruskin University.

HAPPY BIRTHDAY — to David Edelman, Ropes & Gray’s Abby Cable; former Gov. Charlie Baker senior adviser and the NCAA’s Tim ...

Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...